Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow. - Wikidata - awgldk - TriplyDB

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

http://www.wikidata.org/entity/Q30482804

about

Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47 Dinosaurs and ancient civilizations: reflections on the treatment of cancer Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest Neoplasia: the second decade.Molecular regulation of tumor angiogenesis and perfusion via redox signaling.A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.Efficiency of calcium phosphate composite nanoparticles in targeting Ehrlich carcinoma cells transplanted in mice.Therapeutic Targeting of CD47 to Modulate Tissue Responses to Ischemia and Radiation.CD36 as a therapeutic target for endothelial dysfunction in stroke.Original insights on thrombospondin-1-related antireceptor strategies in cancer.Identification of TAX2 peptide as a new unpredicted anti-cancer agent.Thrombospondin-1 and CD47 limit cell and tissue survival of radiation injury.Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies The War on Cancer rages on.Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.Autocrine stimulation of clear-cell renal carcinoma cell migration in hypoxia via HIF-independent suppression of thrombospondin-1.Automated image analysis of intra-tumoral and peripheral endocrine organ vascular bed regression using 'Fibrelength' as a novel structural biomarker.

P2860

Q24627155-248A6E1E-DCC1-4C23-8B7E-1A5C0C920C8C Q24628746-8FD9969A-29C2-4014-8CA3-0B76166B21D1 Q24657627-0FFD115C-04BA-4076-BA52-82548D2A9362 Q28270624-468937B9-142D-4E9E-AE5D-271CDAE8DCAC Q30484000-54B4CDC8-6F1E-4E3D-B101-CAF21F377FCF Q33572306-3848B0D6-30C1-4E1D-BE54-228737339242 Q33576606-2443D6D7-E90E-4D26-A3DF-E9FCBF39983C Q34904445-8A5E07A5-7ADE-482D-9831-BB286834314F Q35914285-A31D334B-7AED-4D0E-94B9-B37323B4906A Q36011859-1C854623-FF70-4990-8B23-245CE92ACF7A Q36139754-FFD2E23D-37F3-4BF3-A85F-31DBEE994106 Q36221374-2FE93787-720D-4AC9-9460-9BC0EB5B76D4 Q36228487-7C8461CC-0B45-4382-92A8-5823FD28D088 Q36891538-8DF7E0F1-91D1-43F3-B84A-8EF1113AB0C0 Q37385797-68D62E4F-78BE-4F5A-94F0-1A9907AAE904 Q37478602-42573C14-4355-4C10-8359-2CA676DF8089 Q39238169-EA2217C8-BEE5-47B3-BFDB-6BC26D013468 Q39246000-844E0EEB-D75E-47BA-8551-4628DC8C813E Q48253400-7C653566-2891-4513-AF70-F67F8F6F586B

P2860

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

http://www.wikidata.org/entity/Q30482804

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@ast

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@en

type

label

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@ast

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@en

prefLabel

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@ast

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.

@en

P1433

Q30482804-637049CA-C836-44FC-8398-CB7AF5D0095C

P1476

Q30482804-40976CAB-517A-4B1A-A328-CA4AA01437B3

P2093

Q30482804-0A64318E-E7A3-44F8-B77D-73B40FEE624A

Q30482804-4F1ECA0B-7C78-4A03-890A-815DFB7CEBEE

Q30482804-85052930-D820-4FD2-AEAE-1ABDB8BAC358

Q30482804-92E1FB66-4AA3-4C21-A83C-4D375E0013FF

Q30482804-A4699287-275B-46A1-BDB4-93F7E720DD23

Q30482804-CD215B39-1089-488B-A61D-DA917DE96FDD

P2860

Q30482804-00CE6B87-F3AD-4EB2-A6DD-DCB6308EBAEC

Q30482804-01DAABB8-DC26-4B43-A661-45724AB1CA5F

Q30482804-036D5A1F-AC7B-45C1-BA0B-74841DDDF67C

Q30482804-047EC616-85B0-4044-B9AB-F43CFA5C399D

Q30482804-080C5B3B-A6B5-459E-8F0E-D7A7A05F2FD2

Q30482804-0A9D670C-06E7-453A-9156-4E79B1E71E82

Q30482804-137EB881-6408-4085-AC56-32FF9ABE59A5

Q30482804-18751CA5-64E8-4165-8FC7-8236CA72B66E

Q30482804-1B54F889-CD8C-461D-9C48-F714FFF90CCF

Q30482804-2BC94A88-741B-4A99-8D15-4351B475760D

P304

Q30482804-54316B74-1B7F-4611-B489-66423103A5D4

P31

Q30482804-D837488D-92B5-48DC-9959-BAC806399461

P356

Q30482804-50DCCDDD-5CBF-498A-89DC-3CAB4451C00B

P433

Q30482804-03AAAFB5-45D7-4592-9DE7-E83E152FB552

P478

Q30482804-23E3AB22-97E7-4D9D-95A2-FB376B84361E

P50

Q30482804-706255C1-CA10-4213-972E-5BDE2AEDD74A

P577

Q30482804-4907B917-EE49-4E2F-8896-0FD568BBAFBD

P5875

Q30482804-9C9AF83C-FE35-41F2-A42C-3E71AF3F700B

P698

Q30482804-49FA80B4-898C-497E-B9EE-8451DBD86E7A

P932

Q30482804-721D531E-17A5-4F0B-96AC-54C266E7193B

P356

P1433

P1476

Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow

@en

P2093

Caitlin S Shannon

http://www.w3.org/2001/XMLSchema#string

David A Wink

http://www.w3.org/2001/XMLSchema#string

Fuminori Hyodo

http://www.w3.org/2001/XMLSchema#string

Jeff S Isenberg

http://www.w3.org/2001/XMLSchema#string

Lisa A Ridnour

http://www.w3.org/2001/XMLSchema#string

Murali C Krishna

http://www.w3.org/2001/XMLSchema#string

P2860

Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake

Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner

CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1

Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases.

Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II.

Blood flow and oxygenation status of human tumors. Clinical investigations.

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin

Delivery of molecular and cellular medicine to solid tumors.

Nitric oxide and glioma: a target for novel therapy?

P304

886-896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/NEO.08264

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

David D Roberts

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23140977

http://www.w3.org/2001/XMLSchema#string

P698

18670646

http://www.w3.org/2001/XMLSchema#string

P932

2481575

http://www.w3.org/2001/XMLSchema#string